Calvin Cohen

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn et al. · New England Journal of Medicine · 2003 · 915 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacotherapy +16

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

D. William Cameron, Margo Heath‐Chiozzi, Sven A. Danner et al. · The Lancet · 1998 · 542 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease

Kenneth A. Freedberg, Elena Losina, Milton C. Weinstein et al. · New England Journal of Medicine · 2001 · 519 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +14

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills et al. · The Lancet · 2012 · 444 citations

Pharmacy, Pharmacology, Pharmacotherapy +17